COVID-19 Vaccines - Current State and Perspectives 2023
DOI: 10.5772/intechopen.107908
|View full text |Cite
|
Sign up to set email alerts
|

Outer Membrane Vesicles: A Challenging Yet Promising Platform for COVID-19 Vaccines

Abstract: The outer membrane vesicles (OMVs) are vesicles released from Gram-negative bacteria, which present a range of biological applications, such as vaccine adjuvants. OMVs present several pathogen-associated molecular patterns, being immunogenic and capable of triggering different arms of the immune response. Thus, they are suitable for mucosal and parenteral delivery, feasible to obtain and have been used in licensed-vaccines previously. However, the extraction protocols and manipulations can modify OMVs cargo an… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 50 publications
0
2
0
Order By: Relevance
“…GSK’s group B 4CMenB N. meningitidis vaccine (four-component recombinant protein-based serogroup B meningococcus ) was licensed for use in Europe in 2013 [ 202 ], and was first applied in the UK in 2015. As of 2019, no significant adverse effects had been detected [ 203 ].…”
Section: Therapeutic Proposals Based On Extracellular Vesiclesmentioning
confidence: 99%
“…GSK’s group B 4CMenB N. meningitidis vaccine (four-component recombinant protein-based serogroup B meningococcus ) was licensed for use in Europe in 2013 [ 202 ], and was first applied in the UK in 2015. As of 2019, no significant adverse effects had been detected [ 203 ].…”
Section: Therapeutic Proposals Based On Extracellular Vesiclesmentioning
confidence: 99%
“…To date, the most successful examples of the use of OMVs in vaccines are the human anti- Neisseria meningitidis group B (MenB) vaccines, which are used to control specific outbreaks of MenB-associated meningitis as well as to protect against the endemic disease in several countries [ 35 , 36 ]. Several other OMV-based vaccines are presently being developed against animal and human pathogens [ 37 , 38 ].…”
Section: Introductionmentioning
confidence: 99%